|7.04|| +0.02 / +0.28%|
XenoPort, Inc. is a biopharmaceutical company focused on developing and commercializing a portfolio of internally discovered product candidates for the potential treatment of neurological disorders. The company's first product gabapentin enacarbil which is known as Horizant in United States and Regnite in Japan, is developed for the treatment of moderate-to-severe primary restless legs syndrome in adults. The XenoPort holds all other world-wide rights and has co-promotion and certain development rights to gabapentin enacarbil in the United States. The company's pipeline of products candidates includes potential treatments for patients with Postherpetic Neuralgia, Spasticity and Parkinson's disease. XenoPort was founded by Ronald W. Barrett, William J. Dower and Mark A. Gallop on May 19, 1999 and is headquartered in Santa Clara, CA.
|Vincent J. Angotti||Chief Executive Officer & Director|
|William G. Harris||Chief Financial Officer & Senior VP-Finance|
|Richard K. Kim||Chief Medical Officer & SVP-Clinical Development|
|Jacqueline Cossmon||Senior Director-Investor Relations|
|Thomas P. McCracken||Secretary|